Leopoldina Statement on the Development of RNA-based Therapies

The German National Academy of Sciences Leopoldina has published a statement on the development of RNA-based therapies. Academy sets recommendations on how these treatment options can be established as a strategic field for the future in Germany.

Prof. Dr. Dagmar Fischer from the Chair of Pharmaceutical Technology and Biopharmaceutics at FAU was a member of the working group that group investigated different RNA-based strategies, provides an overview of current developments, and discusses the societal relevance of RNA-based medicine. It  developed recommendations for research policy and healthcare and highlighted the importance of effective risk communication. Finally, the statement is intended as a contribution to actively shaping the future of this promising type of medicine and to pave the way for innovative treatments which have the potential to fundamentally change healthcare.

Further information:

Leopoldina: RNA-basierte Therapien